← Issue №14/ week of Oct 4, 2026/Pancreas/Biliary

Prevalence and Clinical Significance of Abnormal Findings on Pre-Diagnostic Imaging in Pancreatic Ductal Adenocarcinoma.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary prospective cohort · n=733 · Oct 1, 2026 · Pancreas · IF 1.9

Prevalence and Clinical Significance of Abnormal Findings on Pre-Diagnostic Imaging in Pancreatic Ductal Adenocarcinoma.

New evidencepancreatic cancerepidemiologyartificial intelligence
Clinical takeawayConsider closer surveillance for patients with subtle pancreatic abnormalities (e.g., duct dilation, pancreatic atrophy) on pre-diagnostic imaging, as these may represent early signs of PDAC, but weigh the potential risks of overdiagnosis and unnecessary procedures.
What it found20.6% of PDAC patients (mean age 72.6 y, 53.6% F) had pre-diagnostic imaging, with 27.2% showing abnormal pancreaticobiliary findings, including duct dilation and pancreatic atrophy, which were more frequent than in non-PDAC scans (P=0.04).
ContextThis study highlights the potential for early detection of PDAC through closer scrutiny of pre-diagnostic imaging findings, challenging the current practice of overlooking subtle abnormalities. The findings apply to an older population (mean age 72.6 y, 53.6% F).
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Moy BM … Keswani RN · Pancreas · IF 1.9 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues